Building Blocks; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
Delanzomib is an orally active proteasome inhibitor. Delanzomib has been shown to down-modulate NF-κB, induce apoptosis, inhibit angiogenesis and M-CSF-RANKL-induced osteoclastogenesis.